首页> 美国卫生研究院文献>Frontiers in Neurology >Linking Individual Patient Data to Estimate Incidence and Prevalence of Parkinsons Disease by Comparing Reports of Neurological Services and Pharmacy Prescription Refills at a Nationwide Level
【2h】

Linking Individual Patient Data to Estimate Incidence and Prevalence of Parkinsons Disease by Comparing Reports of Neurological Services and Pharmacy Prescription Refills at a Nationwide Level

机译:通过比较全国范围内神经系统服务和药房处方补充的报告将个人患者数据链接起来以估计帕金森氏病的发病率和患病率

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

>Objectives: We set forth to estimate the number of those with Parkinson's disease (PD) in Hungary, a country with a single-payer health insurance system covering 10 million inhabitants.>Methods: We analyzed all hospital and outpatient reports from neurological services and pharmacy reports of prescription refills. We cross-checked clinically administered diagnosis of PD with prescription refills of antiparkinsonian medications using record linkage. We used the ICD-10 code of G20 in any diagnostic category to find all cases with possible PD. For case certification those patients were considered to have PD who were recorded with G20 code in at least 2 calendar years. For a more conservative estimation we determined the number of those who also refilled antiparkinsonian medication.>Results: Between 2010 and 2012 there were 46,383 subjects with certified PD by clinical criteria. Crude and age-standardized incidence were 49/100,000/year (95% CI: 45–53), and 56/100,000/year (95% CI: 51–60). Crude and age standardized prevalence rates were 404/100,000 (95% CI: 392–416) and 471/100,000 (95% CI: 456–485). Of all clinically certified PD patients 72% refilled antiparkinsonian medications.>Discussion: The incidence and prevalence of PD in Hungary is higher than earlier estimates, which should be considered in organizing healthcare services for this patient group.
机译:>目标:我们着手估算匈牙利的帕金森氏病(PD)人数,匈牙利是一个采用单一付款人健康保险体系,覆盖1000万居民的国家。>方法:我们分析了神经科服务中所有医院和门诊报告以及处方笔芯的药房报告。我们使用记录链接对抗帕金森病药物的处方笔芯对PD的临床诊断进行了交叉检查。我们在任何诊断类别中都使用了G20的ICD-10代码来查找所有可能的PD病例。对于病例证明,那些患者至少在2个日历年内被视为具有PD记录的PD。为了进行更保守的估计,我们确定了也补充抗帕金森病药物的人数。>结果:在2010年至2012年之间,有46,383名通过临床标准认证的PD患者。粗略和年龄标准化的发病率分别为49 / 100,000 /年(95%CI:45–53)和56 / 100,000 /年(95%CI:51–60)。粗略和年龄标准化的患病率分别为404 / 100,000(95%CI:392-416)和471 / 100,000(95%CI:456-485)。在所有临床认证的PD患者中,有72%补充了抗帕金森病药物。>讨论:在匈牙利,PD的发生率和患病率高于先前的估计,在为该患者组组织医疗服务时应考虑到这一点。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号